EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment

Nicola Ferri, Sara De Martin, James Stuart, Sergio Traversa, Andrea Mattarei, Stefano Comai, Franco Folli, Marco Pappagallo, Clotilde Guidetti, Charles E Inturrisi, Paolo L Manfredi

Drugs in R&D · 2024

DOI: 10.1007/s40268-024-00477-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs in R&D, 2024. Verfasst von Nicola Ferri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine-DIMED, University of Padua, 35128, Padua, Italy. nicola.ferri@unipd.it. Hauptthemen laut MEDLINE: Methadone, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Esmethadone (dextromethadone; d-methadone; S-methadone (+)-methadone; REL-1017) is a low potency N-methyl-D-aspartate (NMDA) receptor channel blocker that showed a rapid and sustained adjunctive antidepressant effects in patients with major depressive disorder with inadequate response to ongoing serotonergic antidepressant treatment. Previous studies indicated that esmethadone is partially excreted by the kidney (53.9% of the dose) and by the liver (39.1% of the dose). METHODS: Here we studied the pharmacokinetics and safety of esmethadone after a single oral dose of 25 mg in subjects with different stages of kidney and liver impairment. RESULTS: In subjects with a mild and moderate decrease in glomerular fraction rate (GFR), esmethadone Cmax and AUC0-inf values did not differ compared with healthy subjects. In patients with severe renal impairment, the ratios of Cmax and AUC0-inf values compared with healthy subjects were above 100% (138.22-176.85%) and, while modest, these increases reached statistical significance. In subjects with end stage renal disease (ESRD) undergoing intermittent hemodialysis (IHD), Cmax and AUC0-inf values were not statistically different compared with healthy subjects. IHD did not modified plasma total esmethadone concentrations in blood exiting versus entering the dialyzer. Dose adjustment is not warranted in subjects with mild-to-moderate impaired renal function. Dose reduction may be considered for select patients with severe renal disfunction. In subjects with mild-or-moderate hepatic impairment, Cmax and AUC0-inf were approximately 20-30% lower compared with healthy controls. The drug free fraction increased with the severity of hepatic impairment, from 5.4% in healthy controls to 8.3% in subjects with moderate hepatic impairment. CONCLUSION: Mild and moderate hepatic impairment has a minimal to modest impact on exposure to total or unbound esmethadone and dose adjustments are not warranted in subjects with mild and moderate hepatic impairment. Administration of esmethadone was well tolerated in healthy adult subjects, in subjects with mild or moderate hepatic impairment, and in subjects with mild moderate or severe renal impairment, including patients with ESRF undergoing dialysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethadoneRenal Insufficiency, ChronicHumansMaleFemaleMiddle AgedAdultLiver DiseasesAgedArea Under CurveYoung AdultAdministration, OralGlomerular Filtration Rate

Substanzen

Methadone

Autor:innen und Institutionen

  • Department of Medicine-DIMED, University of Padua, 35128, Padua, Italy. nicola.ferri@unipd.it.
  • Veneto Institute of Molecular Medicine, 35129, Padua, Italy. nicola.ferri@unipd.it.
  • Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35122, Padua, Italy.
  • Relmada Therapeutics, Coral Gables, FL, 33134, USA.
  • Department of Health Sciences, University of Milan, 20122, Milan, Italy.
  • Child and Adolescent Neuropsychiatry Unit, Department of Neuroscience, Bambino Pediatric Hospital, IRCCS, Rome, Italy.

Zitieren

APA

Ferri, N., De Martin, S., Stuart, J., Traversa, S., Mattarei, A., Comai, S., Folli, F., Pappagallo, M., Guidetti, C., Inturrisi, C. E., & Manfredi, P. L. (2024). Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment. Drugs in R&D. https://doi.org/10.1007/s40268-024-00477-3

Vancouver

Ferri N, De Martin S, Stuart J, Traversa S, Mattarei A, Comai S, et al. Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment. Drugs in R&D. 2024. doi:10.1007/s40268-024-00477-3

BibTeX
@article{Ferri2024,
  author = {Ferri, Nicola and De Martin, Sara and Stuart, James and Traversa, Sergio and Mattarei, Andrea and Comai, Stefano and Folli, Franco and Pappagallo, Marco and Guidetti, Clotilde and Inturrisi, Charles E and Manfredi, Paolo L},
  title = {Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment},
  journal = {Drugs in R&D},
  year = {2024},
  doi = {10.1007/s40268-024-00477-3}
}
Kostenlos starten →